Exam 50- Antineoplastic Flashcards

1
Q

tumor initiation and progression

A
  1. genetic mutation leads to abnormal proliferation
  2. more mutations occur within cells
  3. advantageous mutations are selected so tumor becomes increasing malignant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

___ cells before cancer is identified

A

10 billion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

adverse affects of antineoplastic drugs to blood

A

anemia (low RBC)
thrombocytopenia (low platelet)
leukopenia (low WBC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

adverse affects of antioplastic drugs to the GI

A
nausea
vomiting
diarrhea
anorexia
mucositis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

other advers affects of antioplastic drugs

A

opportunistic infections
alopecia (hair cells)
teratogenesis
secondary cancers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

rationale for combined therapy

A
  1. decreased resistance
  2. increase tolerability
  3. increase efficacy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

combination therapy combines drugs with different:

A

MOA
cell cycle phase activity
dose-limiting toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Hodgkin’s Lymphoma combination therapy

A
ABVD
A=doxorubicin (G2)
B=bleomycin (G2)
V=vinblasine (M)
D=dacbazine (G1 and S)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

G1 phase

A

prep for DNA replicatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

S phase

A

DNA replication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

G2 phase

A

prep for mitotis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

M phase

A

=Mitosis

separate of daughter chromosomes and cell division

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Check points of Cell Cycle

A
  1. DNA damage checkpoint- in G1
    - detects damage before entering S as DNA’s being synthesized
  2. Spindle checkpoints - in M
    detect any failure of spindle fibers to form properly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Phase specific drugs general

A
  • most active at a particular phase of the cell cycle
  • time dependent!!
  • more effective against tumors exhibiting log growth pattern
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

phase non-specific drugs

A
  • exert toxic effects on cell during cycle, but not a specific part
  • effective in both high and low growth fraction tumors
  • concentration dependent!! ∴ give highest dose tolerable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

DNA Damaging Agents

A
  1. Alkylating agents

2. Antitumor antibiotics

17
Q

alkylating agnets

A

dacarbazine

  • covalently couples alkyl groups to nucleophillic sites on DNA =APOPTOSIS
  • phase non-specific although peak at late G1 and S phases
  • mutagenic, carcinogenic
18
Q

antitumor antibiotics

A
phase-nonspecivic: although cell is arrested in G2
doxorubicin
-binds to and inhibits DNA function
bleomycin
-binds to DNA and causes free radicals
19
Q

doxorubicin MOA

A

binds to DNA and prevents strand passage and relegation (joining) by topoisomerase II

20
Q

bleomycin MOA

A

binds to DNA and chelates Fe
-accumulates free radicals

also causes pulmonary fibrosis

21
Q

Microtubule function inhibitors

A

vinca alkaloids
(and taxanes)

M phase specific

22
Q

vinca alkaloids

A

vinblasitne

  • bind to alpha and beta tubulin
  • prevents spindle formation and leads to an inability of cells to secrete chromosomes and cell death
23
Q

Inhibitors of DNA Synthesis (types)

A

folate synthesis inhibitors
antimetabolites
topoisomerase inhibitors

Phase S specific

24
Q

antimetabolites

A

purine antagonists
=thioguanine
pyrimidine antagoinsts

MOA= insert into DNA and cause
chain termination
strand breakage
inhibition of cell growth

phase S

25
folate analogues
methotrexate - inhibits dihydrofolate reductase - this enzyme converts dihydrofolate to tetrahydrofolate and eventually into purines treatment= lethal dose of methotrexate followed by foiling acid -rescues cells less dependent on purine synthesis S phase
26
topoisomerase inhibitors
topotecan - S phase specific - inhibits topoisomerase I active in S phase
27
topoisomerase I
unravels DNA helix for replication
28
primary resistance to chemotherapy
1. mutations of p53 - enzyme that shunts to apoptosis, if mutated won't catch alkylation 2. compromised mismatch repair enzyme family - enzymes that repair problems with nicked strands, mismatched DNA or chain termination are compromised os they don't send cell to programmed cell death
29
acquired resistance to chemotherapy
due to drug use, not inherent to cancer 1. resistance to specific drug -reduced drug uptake, or drug deactivation 2. broad resistance to many drugs =increased MDR1 expression -codes a cell surface protein that enhances drug efflux form cell
30
bevacizumab
- antiangiogenic - inhibit tumor blood vessel growth - targets vascular endothelial GF - monoclonal antibody ∴ immunotherapy
31
tamoxifen
=Selective Estrogen Receptor Modulator (SERM) 1. antagonist to ER in breast =inhibits growth-promoting proteins ∴ breast cancer 2. partial agonist to ER in endometrium =increases risk for endometrial cancer
32
Hep B cancer
=DNA virus | associated with liver cancer
33
HPV cancer
=DNA virus | associated with cervical cancer
34
Herpesviruses cancer
=DNA Virus associated with Burkitt's lymphoma Kaposi's sarcoma nasopharyngeal carcinoma
35
Hep C cancer
=RNA virus | associated with liver
36
Retrovirus cancer
=RNA virus | associated with adult T-cell leukemia
37
Gardasil
prevents infection from HPV types 6, 11, 16, and 18 16 and 18 -> cervical cancer 6 and 11 -> genital warts
38
oncogenes
genes that promote cell proliferation and inhibit programmed cell death -if mutated or over expressed = mitosis normal cells require growth factors, but mutations result in growth factor independence
39
imatinib
=Kinase inhibitor BCR-ABL gene => fusion protein (continuously active kinase) -imatinib = 50-95% of puts with chronic myeloid tumor